Hepatitis C and substance use: New treatments and novel approaches

Current Opinion in Psychiatry

Volumn 25, Issue 3, 2012, Pages 206-212

  North, Carol S ^a   Hong, Barry A ^b   Kerr, Thomas ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

boceprevir; hepatitis C; substance abuse dependence; telaprevir; treatment outcomes

Indexed keywords

BOCEPREVIR; CITALOPRAM; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; INTERFERON; PSYCHOTROPIC AGENT; RIBAVIRIN; TELAPREVIR;

DRUG ABUSE; DRUG MECHANISM; DRUG METABOLISM; END STAGE LIVER DISEASE; HEPATITIS C; HUMAN; MENTAL DISEASE; PSYCHOEDUCATION; REMISSION; REVIEW; SUBSTANCE ABUSE; UNITED STATES;

ANTIVIRAL AGENTS; ATTITUDE OF HEALTH PERSONNEL; DRUG THERAPY, COMBINATION; HEALTH SERVICES ACCESSIBILITY; HEPATITIS C; HUMANS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; SUBSTANCE-RELATED DISORDERS;

EID: 84859435220     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0b013e328351f85a     Document Type: Review

References (40)

1. Bacon BR, Gordon SC, Lawitz E, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364:1207-1217.
2. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
3. Wendling P. Telaprevir raises SVR for all IL28B genotypes in hep C. GI & Hepatology News 2011; 5:1, 25. American Gastroenterology Association Institute, Elsevier Global Medical News. http://www.gastro.org/ journalspublications/ gi-hepatology-news/GI-Hepatology-News-June-2011.pdf. [Accessed 29 November 2011]
4. Mallet V, Vallet-Pichard A, Pol S. New trends in hepatitis C management. Presse Med 2010; 39:446-451.
5. Volk ML. Antiviral therapy for hepatitis C: why are so few patients being treated? J Antimicrob Chemother 2010; 65:1327-1329.
6. Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
7. National Institutes of Health. Consensus development conference statement: management of hepatitis C. Hepatology 2002; 36(5 Suppl 1):S3-S20.
8. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006; 144:705-714. (Pubitemid 46780630)
9. O'Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology 2008; 134:1764-1776. (Pubitemid 351615410)
10. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology 2002; 36:S21-S29. (Pubitemid 35253460)
11. Yoon, Y-H, Yi, H-Y. Liver Cirrhosis Mortality in the United States, 1970-2007. Arlington, VA: National Institute on Alcohol Abuse and Alcoholism, Division of Epidemiology and Prevention Research; 2010. NIAAA Surveillance Report No. 88.
12. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009; 49:561-573.
13. Maheshwari A, Ray S, Thuluvath PJ. Acute hepatitis C. Lancet 2008; 372:321-332. (Pubitemid 352020441)
14. Korthuis PT, Feaster DJ, Gomez ZL, et al. Injection behaviors among injection drug users in treatment: The role of hepatitis C awareness. Addict Behav 2011. [Epub ahead of print]
15. Prati D. Transmission of hepatitis C virus by blood transfusions and other medical procedures: a global review. J Hepatol 2006; 45:607-616. (Pubitemid 44316867)
16. Nelson PK, Mathers BM, Cowie B, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378:571-583.
17. Davis GL, AlterMJ, El Serag H, et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138:513-521; 521.
18. Rifai MA, Moles JK, Short DD. Hepatitis C treatment eligibility and outcomes among patients with psychiatric illness. Psychiatr Serv 2006; 57:570-572.
19. Zein NN. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13:223-235. (Pubitemid 30205426)
20. National Institutes of Health Consensus Development Conference Panel. Management of hepatitis C. Hepatology 1997; 26(3 Suppl 1):2S-10S.
21. Sylvestre DL. Hepatitis C in drug users: what to do? Hepatitis C Support Project (2006). http://www.hcvadvocate.org/hcsp/articles/IDU.html. [Accessed 18 November 2011]
22. Zanini B, Covolo L, Donato F, et al. Effectiveness and tolerability of combination treatment of chronic hepatitis C in illicit drug users: meta-analysis of prospective studies. Clin Ther 2010; 32:2139-2159.
23. Jovanovic M, Jovanovic B, Potic M, et al. Characteristics of chronic hepatitis C among intravenous drug users: a comparative analysis. Bosn J Basic Med Sci 2010; 10:153-157.
24. Lowry DJ, Ryan JD, Ullah N, et al. Hepatitis C management: the challenge of dropout associated with male sex and injection drug use. Eur J Gastroenterol Hepatol 2011; 23:32-40.
25. Angeli E, Mainini A, Meraviglia P, et al. Eligibility and feasibility of the treatment of chronic hepatitis C in a cohort of Italian HIV-positive patients at a single HIV reference center. AIDS Patient Care STDS 2011; 25:295-301.
26. Altice FL, Kamarulzaman A, Soriano VV, et al. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 2010; 376:367-387.
27. Schulte B, Schutt S, Brack J, et al. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend 2010; 109:248-251.
28. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010; 4:20-26.
29. Waizmann M, Ackermann G. High rates of sustained virological response in hepatitis C virus-infected injection drug users receiving directly observed therapy with peginterferon alpha-2a (40KD) (PEGASYS) and once-daily ribavirin. J Subst Abuse Treat 2010; 38:338-345.
30. Sasadeusz JJ, Dore G, Kronborg I, et al. Clinical experience with the treatment of hepatitis C infection in patients on opioid pharmacotherapy. Addiction 2011; 106:977-984.
31. Taylor LE, Bowman SE, Chapman S, et al. Treatment for hepatitis C virus genotype 1 infection in HIV-infected individuals on methadone maintenance therapy. Drug Alcohol Depend 2011; 116:233-237.
32. Melin P, Chousterman M, Fontanges T, et al. Effectiveness of chronic hepatitis C treatment in drug users in routine clinical practice: results of a prospective cohort study. Eur J Gastroenterol Hepatol 2010; 22:1050-1057.
33. Manolakopoulos S, Deutsch MJ, Anagnostou O, et al. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010; 30:1454-1460.
34. Gardenier D, Wisnivesky J, McGinn LK, et al. Hepatitis C treatment completion in individuals with psychiatric comorbidity and depression. Gastroenterol Nurs 2011; 34:102-106.
35. Hong BA, North CS, Pollio DE, et al. The use of psychoeducation for a patient with hepatitis C and psychiatric illness in preparation for antiviral therapy: a case report and discussion. J Clin Psychol Med Settings 2011; 18:99-107
36. Grebely J, Knight E, Genoway KA, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010; 22:270-277.
37. Rizza SA, Talwani R, Nehra V, et al. Boceprevir. Drugs Today (Barc) 2011; 47:743-751.
38. Wyszynski AM, Wyszynski M, editors Manual of Psychiatric Care for the Medically III. Washington, DC: American Psychiatric Publishing, Inc.; 2005.
39. Schellander R, Donnerer J. Antidepressants: clinically relevant drug interactions to be considered. Pharmacology 2010; 86:203-215.
40. Myles A, Mugford GJ, Zhao J, et al. Physicians' attitudes and practice toward treating injection drug users with hepatitis C: results from a national specialist survey in Canada. Can J Gastroenterol 2011; 25:135-139.